empliciti elotuzumab 400mg lyophilized powder for iv infusion vial
bristol-myers squibb australia pty ltd - elotuzumab, quantity: 440 mg - injection, powder for - excipient ingredients: sodium citrate dihydrate; citric acid monohydrate; sucrose; polysorbate 80; water for injections - empliciti (elotuzumab) is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
empliciti elotuzumab 300mg lyophilized powder for iv infusion vial
bristol-myers squibb australia pty ltd - elotuzumab, quantity: 340 mg - injection, powder for - excipient ingredients: sodium citrate dihydrate; citric acid monohydrate; sucrose; polysorbate 80; water for injections - empliciti (elotuzumab) is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
biological therapies sodium ascorbate solution 45g/500ml injection bag
orthomolecular medisearch laboratories pty ltd trading as biological therapies - sodium ascorbate, quantity: 90 g/l - injection, intravenous infusion - excipient ingredients: water for injections - sodium ascorbate injections are indicated for the treatment of vitamin c deficiency when oral treatment is not feasible
hospira carboplatin injection 600 mg/60 ml vial
hospira australia pty ltd - carboplatin, quantity: 10 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections - carboplatin is indicated in the treatment of ovarian cancer of epithelial origin and in second line therapy after other treatments have failed.
pfizer (australia) sodium bicarbonate 8.4% (8.4 g/100 ml) injection bp vial
pfizer australia pty ltd - sodium bicarbonate, quantity: 8.4 g - injection, intravenous infusion - excipient ingredients: disodium edetate; water for injections - 1. metabolic acidosis in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis where a rapid increase in plasma total co2 content is crucial. treatment of metabolic acidosis should be concurrent with measures designed to control the cause of the acidosis. 2.urinary alkalinisation in the treatment of certain drug intoxications (ie barbiturates, salicylates, lithium, methyl alcohol) and in the haemolytic reactions requiring alkalinisation of the urine to diminish nephrotoxicity of blood pigments. urinary alkalinisation is also used in methotrexate therapy to prevent nephrotoxicity. 3.severe diarrhoea which is often accompanied by a significant loss of bicarbonate.
zaltrap concentrate for solution for infusion 25 mgml
sanofi-aventis singapore pte. ltd. - aflibercept - infusion, solution concentrate - 25.0 mg/ml - aflibercept 25.0 mg/ml
fluconazole 200mg/100ml infusion bags
bowmed ibisqus ltd - fluconazole - infusion - 2mg/1ml
fluconazole 400mg/200ml infusion bags
bowmed ibisqus ltd - fluconazole - infusion - 2mg/1ml
bendamustine 25 mg powder for concentrate for solution for infusion
actavis group ptc ehf - bendamustine hydrochloride - powder for concentrate for solution for infusion - 25 milligram(s) - nitrogen mustard analogues; bendamustine - antineoplastic agents, alkylating agents - first-line treatment of chronic lymphocytic leukaemia. indolent non-hodgkin's lymphomas. front line treatment of multiple myeloma
bendamustine 100 mg powder for concentrate for solution for infusion
actavis group ptc ehf - bendamustine hydrochloride - powder for concentrate for solution for infusion - 100 milligram(s) - nitrogen mustard analogues; bendamustine - antineoplastic agents, alkylating agents - first-line treatment of chronic lymphocytic leukaemia. indolent non-hodgkin's lymphomas. front line treatment of multiple myeloma.